TransCode Therapeutics Statistics
Share Statistics
TransCode Therapeutics has 696.25K shares outstanding. The number of shares has increased by -89.4% in one year.
| Shares Outstanding | 696.25K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -95.97% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 695.13K |
| Failed to Deliver (FTD) Shares | 133 |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 743.58K, so 106.8% of the outstanding shares have been sold short.
| Short Interest | 743.58K |
| Short % of Shares Out | 106.8% |
| Short % of Float | 106.97% |
| Short Ratio (days to cover) | 0.5 |
Valuation Ratios
The PE ratio is -2.1 and the forward PE ratio is -0.65.
| PE Ratio | -2.1 |
| Forward PE | -0.65 |
| PS Ratio | 0 |
| Forward PS | 5.2 |
| PB Ratio | 23.72 |
| P/FCF Ratio | -2.15 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TransCode Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.
| Current Ratio | 1.28 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -383.66 |
Financial Efficiency
Return on equity (ROE) is -11.3% and return on capital (ROIC) is -928.5%.
| Return on Equity (ROE) | -11.3% |
| Return on Assets (ROA) | -3.59% |
| Return on Capital (ROIC) | -928.5% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.85M |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -98.1% in the last 52 weeks. The beta is 0.65, so TransCode Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.65 |
| 52-Week Price Change | -98.1% |
| 50-Day Moving Average | 10.61 |
| 200-Day Moving Average | 19.67 |
| Relative Strength Index (RSI) | 27.75 |
| Average Volume (20 Days) | 53.40K |
Income Statement
| Revenue | n/a |
| Gross Profit | -516.75K |
| Operating Income | -19.42M |
| Net Income | -18.55M |
| EBITDA | -17.97M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -103.61 |
Balance Sheet
The company has 2.77M in cash and 450.57K in debt, giving a net cash position of 2.32M.
| Cash & Cash Equivalents | 2.77M |
| Total Debt | 450.57K |
| Net Cash | 2.32M |
| Retained Earnings | -46.42M |
| Total Assets | 3.94M |
| Working Capital | 1.33M |
Cash Flow
In the last 12 months, operating cash flow was -18.07M and capital expenditures -35.61K, giving a free cash flow of -18.11M.
| Operating Cash Flow | -18.07M |
| Capital Expenditures | -35.61K |
| Free Cash Flow | -18.11M |
| FCF Per Share | -101.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2792.72% |
| FCF Yield | -701.11% |
Analyst Forecast
The average price target for RNAZ is $20, which is 439.1% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20 |
| Price Target Difference | 439.1% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 4, 2024. It was a backward split with a ratio of 1:33.
| Last Split Date | Dec 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:33 |
Scores
| Altman Z-Score | -31.57 |
| Piotroski F-Score | 1 |